Published in J Neurosci on January 24, 2007
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci (2011) 4.80
The amyloid state of proteins in human diseases. Cell (2012) 4.53
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci (2009) 3.77
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci (2008) 3.25
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J (2010) 2.26
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci (2009) 2.18
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
The prion protein as a receptor for amyloid-beta. Nature (2010) 2.10
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci U S A (2009) 1.75
Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener (2009) 1.73
Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A (2009) 1.69
Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci (2007) 1.68
Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders. Annu Rev Neurosci (2010) 1.68
The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem (2009) 1.67
Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci (2010) 1.64
Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cogn Sci (2011) 1.63
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci (2012) 1.58
Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol (2012) 1.57
Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease. J Neurochem (2011) 1.56
Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem (2009) 1.52
Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci (2007) 1.48
Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am J Pathol (2008) 1.47
Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets (2011) 1.46
Intracellular amyloid β oligomers impair organelle transport and induce dendritic spine loss in primary neurons. Acta Neuropathol Commun (2015) 1.45
Molecular mechanisms of dendrite stability. Nat Rev Neurosci (2013) 1.44
The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron (2013) 1.43
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 1.42
Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. Elife (2015) 1.41
Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility. Mol Neurodegener (2015) 1.40
Wnt-5a/JNK signaling promotes the clustering of PSD-95 in hippocampal neurons. J Biol Chem (2009) 1.38
Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem (2010) 1.37
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease. PLoS One (2010) 1.32
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
Differential progression of structural and functional alterations in distinct retinal ganglion cell types in a mouse model of glaucoma. J Neurosci (2013) 1.31
Insulin receptor signaling in the development of neuronal structure and function. Neural Dev (2010) 1.29
Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem (2011) 1.29
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res (2008) 1.26
GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One (2008) 1.26
Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci (2008) 1.23
The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener (2009) 1.23
NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal (2010) 1.22
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A (2013) 1.22
Amyloid-β as a modulator of synaptic plasticity. J Alzheimers Dis (2010) 1.22
Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A (2011) 1.21
Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem (2009) 1.21
p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem (2008) 1.21
GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A (2009) 1.21
APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct (2009) 1.20
Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci (2010) 1.20
Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis (2009) 1.20
Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci (2009) 1.19
Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer's disease. PLoS One (2009) 1.19
Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem (2009) 1.18
Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One (2011) 1.17
Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One (2010) 1.17
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging (2010) 1.14
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation (2012) 1.13
Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One (2008) 1.12
Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest (2013) 1.12
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Alzheimers Dis (2013) 1.11
Long non-coding RNA-dependent transcriptional regulation in neuronal development and disease. Front Genet (2014) 1.11
Atomic force microscopy and MD simulations reveal pore-like structures of all-D-enantiomer of Alzheimer's β-amyloid peptide: relevance to the ion channel mechanism of AD pathology. J Phys Chem B (2012) 1.11
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol (2012) 1.10
The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Res Ther (2010) 1.09
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol (2009) 1.08
The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease. J Signal Transduct (2012) 1.08
Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2014) 1.07
The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol (2009) 1.07
The effects of cholesterol on learning and memory. Neurosci Biobehav Rev (2010) 1.05
A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med (2008) 5.11
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem (2007) 3.35
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res (2002) 2.88
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell (2013) 2.32
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22
Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc (2005) 2.21
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. Cell Metab (2013) 1.74
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci (2006) 1.69
A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood (2007) 1.69
Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci (2006) 1.66
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
The Apgar score has survived the test of time. Anesthesiology (2005) 1.59
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J (2002) 1.48
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology (2002) 1.28
Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res (2011) 1.26
Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem (2009) 1.21
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology (2010) 1.18
PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem (2006) 1.12
Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci (2003) 1.12
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J Neurochem (2010) 1.10
Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging (2011) 1.09
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol (2009) 1.08
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest (2013) 1.08
The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol (2009) 1.07
Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem Int (2007) 1.04
AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther (2009) 0.98
Amyloid-β triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One (2010) 0.98
Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol (2012) 0.98
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging (2011) 0.97
Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-β peptide oligomers. J Biol Chem (2012) 0.96
Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis (2009) 0.94
Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-d-aspartate receptor in mature hippocampal cultures treated with amyloid-β oligomers. Aging Cell (2012) 0.93
Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci (2013) 0.93
Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett (2009) 0.91
Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med Chem (2004) 0.90
Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis (2012) 0.90
Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci (2012) 0.89
Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets (2009) 0.88
Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. J Alzheimers Dis (2013) 0.87
A glycine zipper motif mediates the formation of toxic β-amyloid oligomers in vitro and in vivo. Mol Neurodegener (2011) 0.87
Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood (2003) 0.86
Soluble state high resolution atomic force microscopy study of Alzheimer's beta-amyloid oligomers. Appl Phys Lett (2009) 0.86
Heat shock treatment reduces beta amyloid toxicity in vivo by diminishing oligomers. Neurobiol Aging (2008) 0.85
Nanodisc-solubilized membrane protein library reflects the membrane proteome. Anal Bioanal Chem (2013) 0.83
Detection and Identification of Bioanalytes with High Resolution LSPR Spectroscopy and MALDI Mass Spectrometry. J Phys Chem C Nanomater Interfaces (2009) 0.83
Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci (2012) 0.82
Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun (2014) 0.82
The pronociceptive effect of ondansetron in the setting of P-glycoprotein inhibition. Anesth Analg (2006) 0.82
Development of the anesthesiology educational milestones. J Grad Med Educ (2014) 0.82
Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols. FASEB J (2012) 0.81
Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb Haemost (2002) 0.81
Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol (2010) 0.81
Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. Curr Alzheimer Res (2007) 0.81
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma (2010) 0.80
Maintaining and fostering the future success of academic anesthesia: recruiting and training the next generation of academic anesthesiologists. Anesth Analg (2013) 0.80
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol (2011) 0.79
Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. J Mol Neurosci (2002) 0.78
Elucidating molecular mass and shape of a neurotoxic Aβ oligomer. ACS Chem Neurosci (2014) 0.78
Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease. Neurobiol Aging (2013) 0.77
Aβ oligomers-induced toxicity is attenuated in cells cultured with NbActiv4™ medium. Neurotox Res (2012) 0.77